Lacosamide Medical Valley

Lacosamide, the active ingredient in Lacosamide Medical Valley, is an anticonvulsant presented as an oral formulation for oral use. It is employed to control partial‑onset seizures in patients with epilepsy, and is commonly prescribed as adjunctive therapy when seizures are not adequately managed by other antiepileptic drugs.

GNH USA supplies Lacosamide Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to essential medicines across global markets.

Lacosamide is an antiepileptic drug that targets neuronal hyperexcitability associated with seizure disorders. - Partial‑onset seizures: reduces seizure frequency when used as adjunctive therapy in epilepsy patients. - Epilepsy (adjunctive therapy): improves overall seizure control when added to existing antiepileptic regimens.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Fatigue: feeling unusually tired. - Diplopia: temporary double vision. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal thoughts or behavior. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Pregnancy: Category C – weigh potential benefits against risks; discuss with obstetrician. - Renal impairment: dose adjustment may be required in severe dysfunction. - Hepatic impairment: monitor liver function tests regularly. - Cardiac conduction: avoid in patients with known PR‑interval prolongation. - Concomitant antiepileptics: monitor for additive CNS depression. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide levels. - Drugs that prolong PR interval (e.g., class I antiarrhythmics): increase risk of cardiac conduction disturbances. - Other sodium‑channel blockers (e.g., lamotrigine) at high doses: may enhance CNS adverse effects.

Moderate Interactions (Monitor Closely): - Alcohol: may potentiate dizziness and somnolence. - Hormonal contraceptives: efficacy may be reduced; consider alternative contraception. - CYP2C19 inhibitors (e.g., fluoxetine): may increase lacosamide plasma concentrations. - Valproate: may require closer monitoring of side‑effect profile. - Digoxin: monitor for possible changes in serum levels.